PI-88, OGT2115, and heparinoids (functional HS) are candidates for diabetes drugs targeting HS because they have HS-like structures and maintain the functions of pancreatic islets and β-cells by compensating for an impaired HS function or by inhibiting heparanase [12,17,152,153,154,155]. This evidence concerns the gene HPSE and diabetes mellitus.